TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20017187
Drug: Higher baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher baseline pain intensity, Hispanic ethnicity, and taking cumulative daily rest time of 35 min or more
Study: 9497653
Drug: Tetracycline‐Hcl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline‐Hcl solution 100 mg/ml for 5 minutes
Study: 2158192
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus extract, administered orally for 1 month
Study: 2559794
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus extract, administered intraperitoneally
Study: 27219124
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (3 g in 500 mL of Ringer)
Study: 27219124
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (6 mL in 500 mL of Ringer)
Study: 20350769
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment (LLT) group, including statin and/or fibrate
Study: 20350769
Drug: No-Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Lipid-lowering treatment (No-LLT) group
Study: 12671333
Drug: Vigorous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigorous treatment of hypertension and use of converting‐enzyme inhibitors
Study: 1718694
Drug: Intrarenal gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarenal gallopamil plus intravenous furosemide (0.5 mg/kg/h for 24 hours)
Study: 6958406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preventive regimens including fluoridated water ingestion, oral hygiene education, dental examinations, prophylaxis, acidulated phosphate fluoride gel (1.23%), pit and fissure sealants, and restorative care
Study: 6958406
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group that continued with preventive regimens
Study: 6958406
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group that did not continue with treatment after 3 years
Study: 16484309
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg daily during menses for up to 5 days each cycle for the first 6 months)
Study: 2864937
Drug: etilefrine pivalate
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etilefrine pivalate (Ep, 20 mg p.o.)
Study: 2864937
Drug: dihydroergotamine (DHE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydroergotamine (DHE, 5 mg)
Study: 27341683
Drug: Triple Combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Combination Therapy (TCT)
Study: 25170594
Drug: Short-term preseasonal
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term preseasonal allergoid immunotherapy
Study: 23787227
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (iCBT) program (the Sadness Program)
Study: 20595412
Drug: Adjunctive SAMe
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive SAMe (800 mg/twice daily)
Study: 16905077
Drug: L-O (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-O (lidocaine with occlusion of IV flow)
Study: 16905077
Drug: L-F (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-F (lidocaine with free IV flow)
Study: 16905077
Drug: L (lidocaine
Normalized name: Lenzagel (lidocaine hydrochloride 4 % / menthol 1 % ) Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (lidocaine pretreatment)
Study: 11720639
Drug: Dalteparin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (120 IU/kg subcutaneously twice daily for more than 6 days)
Study: 8924306
Drug: Exosurf (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (2 x 5 mL/kg doses given 12 h apart, first dose at mean age of 18.7 +/- 3.4 h)
Study: 30785830
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy and autologous stem-cell transplantation (ASCT)
Study: 25710565
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA; 81 mg/day)
Study: 24142681
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G1), without any anti‐arrhythmic drug (AAD)
Study: 21956713
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 150,000 IU every 3 months (n=353)
Study: 21956713
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 150,000 IU every 3 months
Study: 19638596
Drug: Nonprescription nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonprescription nicotine replacement therapy (NRT)
Study: 17580251
Drug: Molecular tools
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular tools for diagnosis and treatment of aortic disease
Study: 15231009
Drug: 10 kcal/kgLBM/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 kcal/kgLBM/day energy availability treatment
Study: 15231009
Drug: All restricted
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All restricted energy availability treatments (10, 20, or 30 kcal/kgLBM/day)
Study: 15231009
Drug: Energy availability
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy availability treatments (20 and 30 kcal/kgLBM/day)
Study: 15231009
Drug: Energy availability
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy availability treatments
Study: 7744561
Drug: 1 microT
Normalized name: BABESIA MICROTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microT (10 mG) electromagnetic fields applied over the right temporal lobe
Study: 7744561
Drug: 1 microT
Normalized name: BABESIA MICROTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microT (10 mG) electromagnetic fields applied over the left temporal lobe
Study: 7744561
Drug: 1 microT
Normalized name: BABESIA MICROTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microT (10 mG) electromagnetic fields applied over both temporal lobes
Study: 2688995
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (200 IU daily) with daily calcium supplement of 500 mg
Study: 4574042
Drug: Prophylactic C.N.S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic C.N.S. treatment (craniospinal irradiation plus intrathecal methotrexate)
Study: 4574042
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic C.N.S. treatment
Study: 20681811
Drug: Hydroxyapatite (HAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite (HAP) in dry sol gel form
Study: 9316825
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg/70 kg
Study: 380610
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg/70 kg
Study: 8352699
Drug: Lovastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20-40 mg)
Study: 3528611
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (mean dose 7.8 +/- 1.2 mg/kg/day)
Study: 31301105
Drug: 4-mm HIGH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mm HIGH treatment
Study: 31301105
Drug: 4-mm LOW
Normalized name: Dianeal Low Calcium 4.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mm LOW treatment
Study: 31301105
Drug: 6-mm HIGH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm HIGH treatment
Study: 31375879
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg daily with bevacizumab 15 mg/kg every 21 days
Study: 31375879
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg every 21 days
Study: 27137713
Drug: Epelsiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epelsiban (10 to 200 mg single-dose; 10 to 150 mg repeat-dose)
Study: 22559997
Drug: Triple test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple test with two antibiotics and one NSAID or two NSAIDs and one antibiotic performed on the same day (n=22)
Study: 22559997
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with drugs taken on three separate days (n=20)
Study: 21654249
Drug: Electrolyzed strongly
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyzed strongly acidic aqueous solution
Study: 19386683
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg daily for 5 days
Study: 12220769
Drug: Flaxseed (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40 g/day)
Study: 12220769
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (0.625 mg conjugated equine estrogens alone or combined with 100 mg micronized progesterone)
Study: 10629707
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy of the breast alone or zones of regional metastasizing (57 patients) with or without adjuvant chemotherapy or hormone therapy (tamoxifen)
Study: 8552892
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy for polymyositis
Study: 1674014
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg daily for 4 weeks
Study: 18437013
Drug: Thoracoscopic procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thoracoscopic procedure and pleurodesis with dextrose solution (group B)
Study: 18437013
Drug: Thoracoscopic procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thoracoscopic procedure and pleurodesis with talc-dextrose mixed solution (group C)
Study: 16482238
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 7 days)
Study: 16482238
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 10 days)
Study: 16482238
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential regimen (esomeprazole 20 mg + amoxycillin 1 g for 5 days, followed by esomeprazole 20 mg, clarithromycin 500 mg, tinidazole 500 mg for 5 days)
Study: 16482238
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 10-day sequential regimen vs 7-day triple therapy
Study: 16482238
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 10-day sequential regimen vs 10-day triple therapy
Study: 16482238
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 7-day triple therapy vs 10-day triple therapy
Study: 6823861
Drug: Labetalol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (intravenous administration)
Study: 6823861
Drug: Labetalol (prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (prolonged oral therapy)
Study: 25051056
Drug: Combination pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Study: 23696676
Drug: Two pills
Normalized name: Two-Dyne Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two pills (angiotensin II receptor blocker and thiazide diuretic)
Study: 19828203
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Study: 18154823
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g)
Study: 18154823
Drug: Triiodothyronine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (0.8 microg/kg bolus and 0.113 microg/kg/h infusion)
Study: 9165973
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg.kg‐1
Study: 1547191
Drug: Probucol 1
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol 1 g/day (4 tablets)
Study: 1547191
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg/day (1 tablet)
Study: 4059587
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nalmefene
Study: 30594227
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Tranexamic acid (TXA) by intravenous injection immediately after the umbilical cord is cut or clamped
Study: 18678826
Drug: 1,800 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg/d EPA-DHA for 26 weeks
Study: 18678826
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d EPA-DHA for 26 weeks
Study: 15672985
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 100 mg, 200 mg, 100 mg, and 200 mg administered at 21:45, 23:45, 01:45, and 03:45
Study: 12799091
Drug: Losartan 2
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 2 x 50 mg/d
Study: 2662830
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 300 mg of pentoxifylline (15 mL ampoules) administered over three hours twice daily.
Study: 2662830
Drug: Placebo: 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily.
Study: 4581347
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg single dose)
Study: 4581347
Drug: Propranolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (30 mg three times a day for one month)
Study: 30745260
Drug: Adjunctive cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) for 2 months
Study: 30745260
Drug: Adjunctive cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) and sham stimulation
Study: 23604570
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy at 5 mg/kg initially given at 0, 2, 6 weeks, then at 8-week intervals.
Study: 23604570
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) >0.5 mg/dL.
Study: 23107346
Drug: L-theanine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine + placebo
Study: 20131184
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 20 ml of bone marrow cells (BMC) after successful primary PCI
Study: 20131184
Drug: Bare metal
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare metal stenting of the infarct-related artery (IRA) without BMC administration
Study: 20131184
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 20 ml of BMC
Study: 10908007
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment offered by the programs at the eight participating sites
Study: 9461944
Drug: 12.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/kg ketamine
Study: 9461944
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg of standard oral premedication (SOP)
Study: 14621723
Drug: Monoclonal immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal immunoglobulins (mIg) identified by agarose gel electrophoresis and immunofixation
Study: 2864892
Drug: Propranolol (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (11 mg)
Study: 2864892
Drug: Hexamethonium (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethonium (910 mg)
Study: 2864892
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg)
Study: 30621047
Drug: Sanghuang⁻Danshen (SD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanghuang⁻Danshen (SD) bioactives at 900 mg/day for 4 weeks
Study: 22791244
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (dispersible tablet)
Study: 22791244
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded capsule)
Study: 20112368
Drug: Org 37663
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37663 (4 mg/day)
Study: 20112368
Drug: Org 37663
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37663 (15 mg/day)
Study: 20112368
Drug: Org 37663
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37663 (50 mg/week)
Study: 18173153
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment for dissolving phlegm and dispelling stasis (DP‐DS)
Study: 11896446
Drug: Vero-IL-2 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero-IL-2 (both doses)
Study: 9019380
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml Healon injected
Study: 9019380
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml Healon injected
Study: 29900874
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg orally twice daily
Study: 22004689
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg nightly for 12 months
Study: 22738796
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine-based acupuncture
Study: 20647199
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² per week for 4 weeks)
Study: 20647199
Drug: Cyclophosphamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2 mg/kg per day)
Study: 17209171
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D dose > or = 250 microg/d (10,000 IU vitamin D3)
Study: 7546499
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg enalapril/HCTZ (group II)
Study: 7546499
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg enalapril/HCTZ (group III)
Study: 2187213
Drug: Lorazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (mean daily dose of 7 mg)
Study: 2187213
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose of 3 mg)
Study: 213186
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG treatment in addition to conventional therapy (surgery, radiotherapy or no treatment)
Study: 213186
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG treatment with a full course of radiotherapy
Study: 213186
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG treatment in patients with squamous carcinoma
Study: 213186
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG treatment in patients with oat cell carcinoma
Study: 31338688
Drug: SAGE-217 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 (0.25 to 66 mg single dose)
Study: 31338688
Drug: SAGE-217 (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 (15, 30, or 35 mg once daily for 7 days)
Study: 22687548
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation condition including the Posit Science Brain Fitness auditory training program with weekly Neuropsychological and Educational Approach to Remediation (NEAR) 'bridging groups'
Study: 22687548
Drug: Computer games
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer games and weekly healthy lifestyles groups (control condition)
Study: 11851739
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injections (up to 4.0 U BOTOX/kg/muscle, 16 U/kg/body weight every 6 months) plus SWASH brace
Study: 11851739
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (BTX‐A/SWASH)
Study: 9611669
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 +/- 2.5 mg)
Study: 9611669
Drug: Olanzapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15 +/- 2.5 mg)
Study: 9611669
Drug: Haloperidol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10-20 mg)